Sunrider Protects from the Sun with the Launch of Oi-Lin® Protective Moisturizer Broad Spectrum SPF 30 Torrance, CA, May 01, 2021 (PR.com) Sunrider International, a global health and wellness direct sales company headquartered in Torrance, California, has recently released Oi-Lin® Protective Moisturizer Broad Spectrum SPF 30, an enhanced reformulation of its best-selling Oi Lin® Deep Moisture Lotion SPF 25. This new ultra-sheer formula has a lighter feel, better absorbency, and even more moisturizing benefits.
Oi-Lin® Protective Moisturizer provides broad-spectrum, mineral-based protection against both UVA and UVB rays while deeply hydrating skin and helping to lock in moisture.
“It’s with genuine excitement that we announce the release of Oi-Lin® Protective Moisturizer,” said Eric Chen, Sunrider’s Chief of Global Manufacturing. “Sun care should be part of our everyday skincare routine, but so often typical sunscreens leave your skin with a streaky, greasy res
Exscientia CEO Professor Andrew Hopkins
Dundee life sciences firm Exscientia has access to almost £400 million after its latest fundraising round.
The Dundee University spin-out company uses artificial intelligence (AI) to design drugs.
Its latest funding round raised $225m (£162m) with an additional $300m (£216m) available from SoftBank at Exscientia’s discretion.
What will the money be used for?
Chief executive Andrew Hopkins said the investment would be used to expand the firm’s drug pipeline and discovery capabilities.
He said: “All of our investors share Exscientia’s vision to discover better drugs, faster, through AI and automation.
Chief executive and founder of Dundee-based Exscientia, Professor Andrew Hopkins.
Exscientia Announces Investment of up to $525M
Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities
$225 million Series D round closed with access up to an additional $300 million at Exscientia s discretion
Financing led by SoftBank Vision Fund 2
Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2
i led the Series D and was joined by previous round lead investors, Novo Holdings and funds managed by Blackrock. Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company s discretion.
Softbank leads $525m round in British drug developer Exscientia
Exscientia chief executive Andrew Hopkins (Photo: Exscientia)
British pharmaceutical company Exscientia has received funding from Softbank Vision Fund just a month after closing its last investment round.
Exscientia uses artificial intelligence to discover new drug molecules and has now designed two drugs that are in Phase 1 of clinical trials.
The Oxford-based company today announced it had completed a $225m Series D round led by the fund, with an additional $300m equity commitment to be drawn down at the pharmatech’s discretion.
The company already has more than 20 active programmes in its pipeline and will use the fresh funding to advance this through clinical testing. It also said the cash will be used to expand Exscientia’s technology platforms.
Place/Date: Palo Alto, CA - April 20th, 2021 at 8:56 pm UTC · 3 min read
The proliferation of decentralized finance (DeFi) continues as a new unicorn is crowned: decentralized derivatives exchange Injective Protocol announced that it has closed $10 million, valuing the network over $1 billion.
A group of prominent new and existing investors who participated in the round include Pantera Capital, BlockTower, Hashed, Cadenza Ventures (formerly BitMex Ventures), CMS, and QCP Capital. It was also reported that billionaire NBA team owner and Shark Tank judge Mark Cuban made a strategic investment into Injective. Cumberland, the crypto arm of one of the largest trading firms DRW, also recently disclosed their investment in Injective.